Maltofer: Which dosage for which patient?
Maltofer®: Effective 7,8,9,15 and better tolerated than iron sulfate11,12,13,15
Maltofer® mechanism of action
Physico-chemical properties of Maltofer® 1-5
- The iron in Maltofer® is bound to a polymaltose complex: it is released slowly and continuously
- Fewer adverse reactions in the digestive tract than iron salts (Fe2+)
- Suitable for vegan, gluten- and lactose-intolerant patients
Maltofer® is effective7,8,9,15
Although iron sulfate initially causes a slightly faster rise in reticulocytes, the rise induced by Maltofer® is comparable after 10 days. 6
Maltofer® is better tolerated than iron sulfate11,12,13,15
Reduced percentage of adverse events with Maltofer® (14.9% vs. 34.1% with iron sulfate) 11
Maltofer®: easy to take with meals
- Convenient administration: Maltofer® can be taken at any time, including during meals 10,17
- Different dosage forms to suit all needs (babies, seniors) 14
- Better adherence to treatment 16
Maltofer®: Oral martial therapy - The right form for everyone
- 4 galenic forms
- No known interactions (except for i.v.*iron)1,11,14
- Can be used in day-care centres
- Reimbursed by health insurance companies
Childbirth, Pregnancy and Breastfeeding
- Each chewable tablet contains 100 mg iron and 0.35 mg folic acid
- For the treatment and prevention of iron deficiency with increased folic acid requirements during pregnancy and breastfeeding 14
- Chocolate-flavoured chewable tablets
Pediatrics - Children and Adolescents
No entries available
References
1. Geisser P et al. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992;42(12):1439–1452.
2. Geisser P und Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011;3(1):12-33.
3. Sharp P und Kaila S. Molecular mechanisms involved in intestinal iron absorption. World J Gastroenterol 2007; 13(35):4716-4724.
4. Schümann K et al. Differences in circulating non-transferrin-bound iron after oral administration of ferrous sulfate, sodium iron EDTA, or iron polymaltose in women with marginal iron stores. Food Nutr Bull 2013;34(2):185-935.
5. Hentze M et al. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117(3):285-297.
6. Borbolla JR et al. Iron hydroxide polymaltose complex vs iron sulphate in the treatment of iron deficiency anaemia in infants. Rev Mex Pediatr 2000; 67: 63-67.
7. Toblli J und Brignoli R. Iron(III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia. Arzneimittelforschung 2007; 57(6A): 431-438.
8. Ortiz R et al. Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study. The Journal of Maternal-Fetal and Neonatal Medicine 2011; 24(11): 1347-1352.
9. Jacobs P et al. Oral iron therapy in human subjects: comparative absorption between ferrous salts and iron polymaltose. Journal of medicine 1984;15(5-6):367-377.
10. Kaltwasser JP, Werner E and Niechzial M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung 987;37(1A):122–129.
11. Lundqvist H und Sjöberg F. Food interaction of oral uptake of iron / a clinical trial using 59 Fe. Arzneimittelforschung 2007; 57(6A): 401-416.
12. Geisser P. Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years' experience. Arzneimittelforschung 2007; 57: 439-452.
13. Kaltwasser JP et al. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung 1987; 37(1A): 122-129.
14. According to Maltofer® and Maltofer Fol® professional information: www.swissmedicinfo.ch.
15. Yasa B et al. Efficacy, tolerability, and acceptability of iron hydroxide polymaltose complex versus ferrous sulfate: A randomized trial in pediatric patients with iron deficiency anemia. Int J Pediatr 2011; 2011: 524-520.
16. Walter T et al. Tolerance and acceptability in infants of iron polymaltose complex. Ars Medici 2005; 9: 428-431.
17. Andrade JVD. Treatment of iron deficiency anaemia with iron-hydroxide polymaltose complex. ARP-Supl Arq Bras Med 1992; 66: 253-258.
Healthcare professionals may request a full copy of the references cited from Vifor Pharma Switzerland SA. Maltofer® professional information: www.swissmedicinfo.ch.